NCT05870319View on ClinicalTrials.gov

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

356

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

May 20, 2025

Study Completion Date

September 30, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

SKB264

intravenous (IV) infusion (Q2W)

DRUG

Pemetrexed

500 mg/m2 intravenous (IV) infusion (Q3W)

DRUG

Carboplatin

AUC 5 intravenous (IV) infusion (Q3W) 4cycles

DRUG

Cisplatin

75 mg/m2 intravenous (IV) infusion (Q3W) 4cycles

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY